GCL
NRXP icon

Glazer Capital LLC’s NRX Pharmaceuticals NRXP Stock Holding History

Glazer Capital LLC’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,698
Closed -$718K – 390
2020
Q3 		$718K Buy
+6,698
New +$721K 0.04% 188
2019
Q2 		– Sell
-15,132
Closed -$1.56M – 166
2019
Q1 		$1.56M Sell
15,132
-1,587
-9% -$163K 0.23% 74
2018
Q4 		$1.71M Sell
16,719
-482
-3% -$48.7K 0.24% 73
2018
Q3 		$1.72M Sell
17,201
-2,020
-11% -$201K 0.18% 82
2018
Q2 		$1.91M Buy
19,221
+32
+0.2% +$3.16K 0.19% 78
2018
Q1 		$1.87M Hold
19,189
– – 0.2% 63
2017
Q4 		$1.86M Buy
+19,189
New +$1.86M 0.3% 48

Other funds holding NRXP

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return

Glazer Capital LLC's NRXP Position: Q4 2020 in Review

Glazer Capital LLC sold out of NRX Pharmaceuticals (NRXP) in Q4 2020, closing a stake of 6,698 shares — an estimated $718K sold.

Glazer Capital LLC first reported a position in NRXP in Q4 2017 and held it in 7 quarters. The position peaked at $1.91M in Q2 2018. 6 funds tracked by Wall St. Rank hold NRXP as of Q4 2020.

  • Glazer Capital LLC reported no remaining NRX Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Glazer Capital LLC sold 6,698 NRX Pharmaceuticals shares in Q4 2020, an estimated $718K.
  • Glazer Capital LLC first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 7 quarters.
  • Glazer Capital LLC's NRX Pharmaceuticals position peaked at $1.91M in Q2 2018.
  • 6 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2020.

Based on Glazer Capital LLC's 13F filing for Q4 2020, filed 16 Feb 2021.